Test Price
220 AED✅ Home Collection Available
GM1 Gangliosidosis Quantitative Blood Test in UAE | 220 AED | DHA Licensed
Executive Summary & Core Metrics
This quantitative beta-galactosidase enzyme activity assay delivers definitive biochemical diagnosis for GM1 gangliosidosis with 99.9% diagnostic sensitivity, processed at our ISO 9001:2015 accredited laboratory. We provide paid VIP mobile phlebotomy with temperature-controlled cold-chain home collection and complimentary post-test telephonic clinical guidance. For direct insurance billing verification, contact us via WhatsApp at +971 54 548 8731.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain & VIP Mobile Phlebotomy.
- Clinical Guidance: Complimentary Telephonic Post-Test Clinical Guidance in Result Interpretation.
- Insurance: Direct Billing Verification via WhatsApp: +971 54 548 8731
Test Overview & Methodology
Quantitative Enzyme Assay for GM1 Gangliosidosis
The GM1 Gangliosidosis Quantitative Blood Test measures beta-galactosidase enzyme activity in peripheral blood leukocytes to confirm diagnosis of GM1 gangliosidosis, a rare autosomal recessive lysosomal storage disorder caused by GLB1 gene mutations. Early biochemical detection enables timely dietary management, symptomatic treatment, and genetic counseling to slow progressive neurodegeneration.
This assay uses ISO-standardized spectrophotometric methodology with fluorogenic substrate 4-methylumbelliferyl-beta-D-galactopyranoside, providing precise quantification of residual enzyme activity critical for differentiating infantile (type I), juvenile (type II), and adult-onset (type III) subtypes when combined with clinical and genetic correlation.
| Feature | Our Test (Enzyme Activity) | Standard Genetic Panel |
|---|---|---|
| Methodology | ISO-Standardized Spectrophotometric Enzyme Assay | Next-Generation Sequencing (NGS) Panel |
| Turnaround Time | 4 Working Days | 10–14 Working Days |
| Precision | CV <5%, LOINC-Coded Traceability | Variant Interpretation Dependent |
| Clinical Utility | Direct Enzyme Confirmation – Gold Standard for Biochemical Diagnosis | Mutation Detection, May Miss Regulatory Mutations |
| DHA Accreditation | MOHAP/DHA Facility License 1143, ISO 9001:2015 (INT/EGQ/2509DA/3139) | Varies by Provider |
Physician Insight & Safety Protocols
“Receiving a suspected diagnosis of GM1 gangliosidosis is profoundly challenging for families. This quantitative enzyme assay provides definitive biochemical evidence that, when interpreted alongside clinical presentation, neuroimaging, and GLB1 molecular analysis, establishes an accurate diagnosis and informs prognosis and care planning. It is critical to understand that this test result must be correlated with a comprehensive clinical evaluation by a metabolic genetics specialist and is not a standalone diagnostic conclusion.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory on Medication & Test Interpretation
Medication Advisory
Do not discontinue any prescribed medication without consulting your supervising physician. This test result alone does not dictate therapeutic changes. Enzyme activity levels can be transiently influenced by acute illness, recent blood transfusion, or certain medications; therefore, all results must be evaluated in full clinical context.
Safety Exclusion Criteria & Emergency Red Flags
Exclusion Criteria & ER Red Flags
- Exclusion: Active hemolysis or blood transfusion within the last 4 weeks may falsely alter enzyme levels. Test only once hematologically stable.
- Exclusion: Platelet or clotting disorders that contraindicate phlebotomy require physician clearance before collection.
- ER Red Flag: If the patient experiences acute seizures, loss of consciousness, respiratory distress, or sudden neurological regression, proceed to the nearest emergency department immediately—do not delay for test results.
- Urgent Referral: Progressive developmental regression, feeding difficulties, or new-onset hypertonia warrant immediate pediatric neurology evaluation.
Patient FAQ & Clinical Guidance
1. What does a low beta-galactosidase level indicate?
A markedly reduced enzyme activity below the normal reference range confirms the diagnosis of GM1 gangliosidosis. The severity of deficiency correlates with disease subtype; trace or absent activity typically indicates infantile (type I) disease, while residual activity may suggest later-onset forms. Genetic testing and clinical assessment are needed for final subtyping.
2. How should I prepare my child for the blood draw?
Ensure your child is well-hydrated, maintain their regular feeding schedule, and provide a complete clinical history and family pedigree to the phlebotomist. No fasting is required; however, if the child is taking any supplements or medications that could interfere with beta-galactosidase activity, inform our medical team before collection. The sample requires 10 mL (minimum 7.5 mL) whole blood collected in 3 lavender-top (EDTA) or green-top (sodium heparin) tubes, transported refrigerated (do not freeze).
3. Can this test differentiate between infantile and juvenile forms?
Quantitative enzyme activity levels alone cannot reliably differentiate subtypes; clinical presentation and genetic analysis are required for accurate subtyping. Extremely low or null activity is strongly suggestive of the infantile form, but overlapping values may occur. Therefore, enzyme results should be integrated with neurological evaluation, brain MRI, and molecular GLB1 gene testing for comprehensive diagnosis.
4. Is genetic counseling recommended after this test?
Yes, genetic counseling is strongly recommended for all families receiving a confirmed diagnosis of GM1 gangliosidosis. This is an autosomal recessive condition with a 25% recurrence risk in future pregnancies. A medical genetics specialist will discuss inheritance patterns, carrier testing for at-risk relatives, prenatal diagnosis options, and available support resources.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Protection
- Data Privacy: All patient data is processed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), ensuring lawful collection, storage, and sharing of health information.
- Health Information Governance: We adhere to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, guaranteeing secure electronic health record management and encrypted data transmission.
- Clinical Safety & Patient Consent: All phlebotomy and diagnostic procedures are conducted under the framework of Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring informed consent, patient safety, and professional accountability.
- Accreditation: DNA Labs UAE operates under DHA Facility License No. 1143 and maintains ISO 9001:2015 certification (INT/EGQ/2509DA/3139) for quality management systems.
Clinical & Logistical Metadata
| Test Name | GM1 Gangliosidosis Quantitative Blood Test (Beta-Galactosidase Enzyme Activity, Leukocytes) |
| Price (AED) | 220 AED |
| Turnaround Time | 4 Working Days |
| Sample Type / Matrix | Peripheral Whole Blood (Leukocytes) – 10 mL collected in 3 Lavender-Top (EDTA) or Green-Top (Sodium Heparin) Tubes; Transport Refrigerated (2–8°C), Do Not Freeze |
| Methodology Used | ISO-Standardized Spectrophotometric Enzyme Assay with Fluorogenic Substrate (4-Methylumbelliferyl-beta-D-Galactopyranoside) |
| ICD-10-CM Code | E75.01 |
| LOINC Code | 21455-5 |
| DHA Facility License & Laboratory Address | DHA Facility License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians